Business Context and Reporting Period
This Form 8-K is a current report filed by Miragen Therapeutics, Inc. (not Viridian Therapeutics, Inc.) on June 30, 2017, regarding events occurring on June 28, 2017. The filing details the results of the Company's 2017 Annual Meeting of Stockholders.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting results.
Material Changes and Voting Results
The primary material event reported is the conclusion of the 2017 Annual Meeting. Key voting statistics include:
- Shareholder Participation: 15,690,519 shares (73.3% of 21,401,828 outstanding) were present or represented by proxy.
- Director Elections: All seven nominees were re-elected. Each received over 15.2 million "For" votes, with approximately 28,000 votes withheld and 439,405 broker non-votes.
- Auditor Ratification: Stockholders ratified the appointment of KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2017. The vote was 15,682,001 "For," 8,432 "Against," and 86 "Abstentions."
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, future outlook, management commentary on operations, specific risks, contingencies, or unusual items. The document is limited to the procedural results of the shareholder vote.
Important Facts for Investors to Verify
- Confirm the correct registrant name is Miragen Therapeutics, Inc., as the input metadata referenced Viridian Therapeutics, Inc.
- Verify the re-election of the seven specific directors listed (Marshall, Booth, Creecy, Hughes, Koch, Lefkoff, and Turner).
- Confirm the ratification of KPMG LLP as the auditor for the 2017 fiscal year.
- Note that this filing contains no financial performance data; refer to the most recent 10-K or 10-Q for financial metrics.